Dilip Shanghvi

Managing director

At just 27, Shanghvi borrowed 10,000 rupees from his father to start a pharmaceutical business. With no formal science education but with gumption, Shanghvi focused on a few niche drugs before embarking on an aggressive acquisition strategy at home and abroad that has transformed Sun Pharmaceuticals into one of the world’s biggest specialty generic drug makers. The company has been involved in almost 20 acquisitions and joint ventures, including the US$4-billion purchase of competitor Ranbaxy Laboratories last year. 


Sun Pharmaceutical Industries

Net worth:

US$19.4 billion